PT  - JOURNAL ARTICLE
ED  - ,
TI  - An update on the bleeding risks associated with DOACs
AID  - 10.1136/dtb.2017.11.0553
DP  - 2017 Nov 01
TA  - Drug and Therapeutics Bulletin
PG  - 129--132
VI  - 55
IP  - 11
4099  - http://dtb.bmj.com/content/55/11/129.short
4100  - http://dtb.bmj.com/content/55/11/129.full
SO  - Drug Ther Bull2017 Nov 01; 55
AB  - The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose–response with fixed doses and limited interactions with food and drugs.1,2 However, these agents have been in widespread clinical use for less than a decade and, compared with extensive experience with warfarin, there is uncertainty relating to optimal laboratory monitoring of anticoagulation, perioperative management and treatment of bleeding.3 In addition, there is currently only one drug licensed in the UK for rapid reversal of the anticoagulant effect of a DOAC. Here, we review DOAC-related bleeding and the role of drugs to reverse the anticoagulant action of DOACs.